home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer
Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer
Post navigation
Previous Post
Previous
C4 Therapeutics Announces Pricing of Public Offering
Next Post
Next
C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma